

## **Entitlement Offer closed successfully raising A\$5.3 Million Tissue Therapies Limited (trading as Factor Therapeutics)**

On 18 March 2016, Tissue Therapies Limited ACN 101 955 088 trading as Factor Therapeutics (ASX:TIS) (**Factor**) announced a 2 for 5, fully underwritten, non-renounceable Entitlement Offer for ordinary shares in Factor (**New Shares**) at an offer price of \$0.035 per share (**Entitlement Offer**) to raise \$5.3 million. This follows on from its successful first tranche placement at the same price per share that raised \$2.7 million. The second tranche placement will raise \$7.0 million subject to Factor shareholder approval. A shareholder meeting is to be held on 28 April 2016.

The Entitlement Offer has been fully underwritten by Taylor Collison Limited (**Underwriter**).

In accordance with the ASX Listing Rules, Factor advises that it has accepted valid applications under the Entitlement Offer for 91.3 million New Shares (\$3.2 million), representing 60.3% of the 151.4 million New Shares offered to eligible shareholders, giving a shortfall of 60.1 million New Shares (\$2.1 million). In assessing valid applications the Company, in consultation with the Underwriter, applied a scaling policy in respect of a small proportion of applications made under the Top Up Facility. The balance of the New Shares are to be allocated by the Underwriter.

The allotment of New Shares under the Entitlement Offer is scheduled to take place on 26 April 2016 and ASX trading of the New Shares is expected to commence on 27 April 2016. Holding statements are expected to be despatched to shareholders on 27 April 2016, which will confirm the number of shares allotted to each applicant.

Executive Director, Dr Christian Behrenbruch, commented, "Considering the challenges that the company has faced over the past 18 months, we view this as a solid response from our shareholder base and we remain committed to re-building trust and confidence in the company and its significant commercial potential."

Chairman, Dr Cherrell Hirst, further commented, "We are appreciative of our existing shareholders for their support during this financing, and for the opportunity enables to implement our revised commercial strategy over the next 12 months."

**- ENDS -**

## **Corporate Contact**

Dr. Christian P. Behrenbruch  
Executive Director  
Tissue Therapies Limited, trading as Factor Therapeutics  
Tel: +61 7 3334 3900  
Email: [c.behrenbruch@factor-therapeutics.com](mailto:c.behrenbruch@factor-therapeutics.com)

## **About Factor Therapeutics**

Tissue Therapies Limited (trading as Factor Therapeutics) is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Factor Therapeutics is commercialising VF-001 (previously denoted VitroGro® ECM), a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The business owns various patent families related to wound healing and other therapeutic uses. The Company's shares are traded on the Australian, Berlin and Frankfurt stock exchanges. For more information, please visit [www.factor-therapeutics.com](http://www.factor-therapeutics.com)

## **Important information**

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. This document may not be distributed or released in the United States.